The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
AusPAR: Ofatumumab
Australian Public Assessment Report
Device/Product Name
Kesimpta
Active ingredients
Ofatumumab
AusPAR Date
Published
Sponsor
Submission Number
PM-2020-00666-1-1
Submission Type
Extension of indications and major variation (new dosage form)
Decision
Approved